European Psychiatry - Volume 33 - March 2016

294 / 812

S290 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
neurological soft signs (r = −0.44), sequence of motor acts sub-
score (r= −0.54) and sensory integration subscore (r = −0.47) in SZ
patients group (P < 0.05).
Conclusions There is association between implicit motor learning
deficits and neurological soft signs in SZ patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW502
First-generation versus
second-generation antipsychotic
drugs for depression in schizophrenia
M. Corbo ∗, T. Acciavatti , S. Marini , E. Cinosi , L. Di Tizio ,
L. Di Caprio , D. Viceconte , L. Matteo , D.I. Giuseppe ,
G. Martinotti , M. Di Giannantonio
University “G.D. Annunzio” Chieti, Neuroscienze- Imaging e Scienze
Cliniche, Chieti, Italy
∗ Corresponding author.
Introduction A certain degree of depressive symptoms is com-
mon in schizophrenic patients. The assessment and treatment of
depressive symptoms in schizophrenia is clinically challenging.
Objectives We conducted a cross-sectional study to investigate
the depressive dimension of schizophrenic patients.
Aims The aim was to evaluate the effect of pharmacotherapy on
depressive symptomatology.
Methods Thirty-four outpatients (18-65 years old) with stable
schizophrenia in monotherapy with FGAs or SGAs. We evalu-
ated: depressive symptoms with Calgary Depression Scale for
Schizophrenia; positive and negative symptoms (with Positive
and Negative Symptom Scale); neurocognition (with Matrics
Cognitive Consensus Battery); social cognition (with Facial Emo-
tional Identification Test); social functioning (with Personal and
Social Performance Scale and with UCSD Performance-based Skills
Assessment). Collected data underwent statistical analyses.
Results A SGAs therapy was associated with: lower depressive
symptoms (mean SGAs group = 4.0; mean FGAs group = 7.86,
P < 0.05); lower mean positive symptoms (mean SGAs
group = 12.65; mean FGAs group = 17.43, P < 0.05); lower
negative symptoms (mean SGAs group = 21.35; mean FGAs
group = 29.07, P < 0.05); lower scores on the PANSS-total (mean
SGAs group = 71.05; mean FGAs group = 91.86, P < 0.01). After cor-
rection for multiple variables, the SGAs group still had significantly
lower values towards the FGAs group (P < 0.05).
Conclusions Our study support the notion that switch from a
FGA to a SGA could be a relatively simple first-step for the treat-
ment of this condition. Atypical antipsychotics might exercise
antidepressant effects with different potential mechanism includ-
ing: remission of a FGA-induced depression and action on of
5-hydroxytryptamine, dopamine [other than postsynaptic D2], and
1-noradrenergic receptor sites.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW503
Clinical and functioning outcomes of
second-generation long-acting
antipsychotics in a sample of
schizophrenia patients during a
follow-up period of 6 months
V. Corigliano ∗, I. Mancinelli , A. De Carolis , S.M. Tamorri ,
S. Di Pietro , F. Pazzelli , I. Ciccaglione , P. Girardi ,
A. Comparelli
1 Sant’Andrea hospital, NESMOS department neurosciences- mental
health and sense organs unit of psychiatry- Sant’Andrea hospital-
school of medicine and psychology- Sapienza university, Roma, Italy
2 Sant’Andrea hospital, NESMOS department neurosciences- mental
health and sense organs unit of psychological medicine- Sant’Andrea
hospital- school of medicine and psychology- Sapienza university,
Roma, Italy
∗ Corresponding author.
Introduction Second-generation long-acting injectable antipsy-
chotics (LAIs) constitute a valuable alternative for the treatment
of schizophrenia and combine advantages of both long-acting
injectable drugs and atypical antipsychotics. Realistic, naturalis-
tic studies are necessary to evaluate the impact of LAIs on specific
cluster of symptoms.
Objectives To collect clinical and functioning outcomes in out-
patients with schizophrenia treated with LAIs during a follow-up
period of 6 months.
Aims To determine the impact on symptoms and functioning of
second-generation LAIs.
Methods It is a 6-month naturalistic, observational, prospec-
tive, non-interventional study of patients diagnosed with DSM-V
schizophrenia disorder. Clinical data were assessed by the Positive
and Negative Syndrome Scale (PANSS) and the Global Assessment
of Functioning (GAF). For statistical analysis, we used the Wall-
work’s five-factor model of the PANSS.
Results A total of 50 schizophrenia patients (70% male; mean
age: 36.2± 10.4) referred to the Depot Clinic at Sant’Andrea Hospi-
tal in Rome was included. Eight patients received treatment with
risperidone LAI (RLAI), 20 with paliperidone-palmitate LAI (PLAI),
10 with olanzapine-pamoate LAI (OLAI) and 12 with aripiprazole
LAI (ALAI). LAIs were overall associated with improved function-
ing and positive symptoms; OLAI, ALAI e PLAI correlated with
improved negative symptoms, RLAI, OLAI e PLAI with improved dis-
organised/concrete symptoms, OLAI e PLAI with improved excited
symptoms; ALAI improved depressive symptoms.
Conclusion Over the 6-month period, LAIs were associated with
improved functioning and illness severity in schizophrenia patients
with different symptoms profile. Treatment with PLAI and OLAI
showed the major clinical advantages, whereas only ALAI corre-
lated with improved depressive symptoms.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW504
Reduction of negative social
attributions towards people with
mental illness through a combination
of treatments
C. Vaquero ∗, M. Cebollero , M.Á. Escudero , J. Saiz
1 Grupo 5, psychosocial rehabilitation, Aranjuez, Spain
2 Universidad Complutense de Madrid, Facultad de Psicología,
Madrid, Spain
∗ Corresponding author.
Introduction Stigma towards people withmental illness can have
very negative consequences for the persons that experience it. So,
it becomes strongly necessary to combat this problem.
Objectives/Aims Evaluate the effectiveness of multiple interven-
tions to reduce stigma against mental illness in a group of high
school students.
Methods Quasi-experimental study. Seventy-six students
between 16 to 19 years old from 3 schools of southern Madrid
State participated. No significant differences in age and gen-
der between groups were found. The quasi-control group was
obtained from 3 different classrooms (1 in each school). This
group did not go through any treatment. The experimental group